SCHEMBL7051256

SCHEMBL7051256

CCOC(=O)C(Cc1ccccc1)CP(=O)(CSc1cccc2ccccc12)OCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.43
EPHX2 P34913 2/20 0.43
PPARA Q07869 1/20 0.38
ACP3 P15309 1/20 0.37
MMP8 P22894 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HPGD P15428 4/20 0.36
LMNA P02545 2/20 0.36
ELANE P08246 1/20 0.36
HPRT1 P00492 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
THRB P10828 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
F9 P00740 1/20 0.35
F10 P00742 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052110 0.91 HPGD (0.37) PPARGEPHX2HSD17B10HPGDLMNA
SCHEMBL7052124 0.89 EPHX2 (0.34) PPARGEPHX2HSD17B10HPGDLMNA
SCHEMBL7244415 0.89 POLB (0.38) HPGDLMNAKDM4EALDH1A1MEN1
SCHEMBL7050180 0.88 HSD17B10 (0.43) HSD17B10HPGDLMNAKDM4EALDH1A1
SCHEMBL7052860 0.84 EPHX2 (0.46) PPARGEPHX2PPARAMMP8HSD17B10
SCHEMBL7049822 0.83 PPARG (0.43) PPARGEPHX2PPARAMMP8HSD17B10
SCHEMBL7054019 0.83 ACP3 (0.43) ACP3HSD17B10HPGDLMNAKDM4E
SCHEMBL7049089 0.81 PRNP (0.52) PPARGEPHX2MMP8LMNAELANE
SCHEMBL7049872 0.78 EPHX2 (0.51) PPARGEPHX2PPARAMMP8HSD17B10
SCHEMBL7049049 0.75 ERAP2 (0.46) ACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 PPARG 3903/4885EPHX2 2309/4885PPARA 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.